Explorna Therapeutics Receives Funding To Advance Its Novel Mrna Technology
12/07/22, 2:05 PM
Location
warsawIndustry
therapeutics
pharmaceutical
biotechnology
health care
ExPLoRNA Therapeutics, a Polish biotech company revolutionizing mRNA vaccines and therapeutics with unprecedented translational efficiency, received funding from the Bill & Melinda Gates Foundation to further develop its unique mRNA technology. ExPLoRNA specializes in novel cap analogs, the starting part of mRNA that is crucial for enabling successful production of the encoded protein. ExPLoRNA's technology increases protein production beyond scale observable so far with other standard cap analogs.
Company Info
Location
warsaw, masovian voivodeship, poland
Additional Info
Our mission is to deliver mRNA technology innovations to revolutionize future therapies and the prevention of many diseases. We invent, develop, manufacture and apply our solutions for the benefit of pharmaceutical partners, and to improve people’s lives.
With passion, ExploRNA Therapeutics develops ground-breaking innovations of mRNA as a therapeutic platform, applies those solutions in unique therapeutic programs, and delivers technology, therapeutic platform, and therapies to pharmaceutical partners.
The future of healthcare belongs to therapeutic mRNA